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Abstract
The in vitro susceptibility profile to amikacin, linezolid, clarithro-
mycin, imipenem, cefoxitin, clofazimine and tigecycline was
established for 67 strains belonging to the Mycobacterium abscessus
complex. Clofazimine and tigecycline were among the most
effective drugs, prompting us to assess the effect of a clofazimine
and tigecycline combination. Synergistic activity was found in 42%
of the 19 isolates tested. The clinical impact of this new drug
combination against the M. abscessus complex, as an alternative or
sequential medication for the treatment of drug-resistant strains,
remains to be addressed.
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Rapidly-growing mycobacteria (RGM) comprise species with
increasing clinical importance, of which the Mycobacterium
abscessus (Mabs) complex represents the most significant one
[1]. This complex is subclassified into three subspecies, based
on whole genome sequencing [2,3]: M. abscessus subsp.
abscessus, M. abscessus subsp. bolletii and M. abscessus subsp.
massiliense [4,5]. The distinction between these subspecies is
clinically relevant because they respond differently to antibi-
otics [6]. Among RGM, the Mabs complex possesses the
greatest capacity to colonize the respiratory tract and causes
disease in patients with cystic fibrosis (CF) [7], associated with
poor clinical outcome [8]. The importance of this complex in
healthcare-associated diseases and in surgical tourism-associ-
ated infections also increases [9]. It comprises the most
drug-resistant mycobacterial species [10] and treatments
remain extremely challenging. Combination therapy that
includes at least one effective aminoglycoside is strongly
recommended for an effective treatment regimen [1]. However,
few studies addressed the possible synergy of drug combina-
tions against Mabs and given the lack of new active molecules,
exploring the synergy between existing drugs represents a
sensible way to achieve better treatment combinations.
Therefore, we first determined the drug susceptibility profile
of a panel ofMabs complex isolates fromCF and non-CF patients
obtained between January 2008 and December 2013 at the
Microbiology Laboratory, University Hospital, Montpellier,
France. Species identification was performed using the Geno-
Type Mycobacterium CM kit (Hain Lifescience, Nehren, Ger-
many) and the multilocus sequence typing method (MLST) [11].
Most isolates were recovered from respiratory specimens.
Among the 67 M. abscessus strains collected, 42 were subsp.
abscessus, 21 subsp. massiliense and four subsp. bolletii. All were
tested against amikacin, linezolid, clarithromycin, clofazimine
(Sigma, Saint Quentin Fallavier, France), imipenem/cilastatin
(Mylan, Saint-Priest, France), tigecyline (Pfizer, Amboise,
Amboise, France) and cefoxitin (Panpharma, Fougeres, France).
MICs were determined according to the CLSI guidelines [12].
The broth microdilution method was used in Cation-Adjusted
Mueller-Hinton Broth (CAMHB) with an inoculum of
5 9 105 CFU/mL in the exponential growth phase; 100 lL of
drug dilutions were added to 100 lL of bacterial suspension and
incubated at 30°C for 4 days. MICs were recorded by visual
inspection and by absorbance at 560 nm to confirm visual
recording. The categorization S/I/R for each antimicrobial was
established according to the CLSI breakpoints [12].
MICs against the seven antimicrobials (Table 1) indicate that
87% of Mabs complex strains (58/67) were susceptible to
amikacin whereas 12% (8/67) displayed intermediate suscep-
tibility and 4% (3/67) were resistant. Eighty-four per cent of
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isolates (56/67) were susceptible and 7% (5/67) were resistant
to linezolid. Clarithromycin proved to be the drug with the
highest frequency of resistant strain (33%) (for a short
duration of incubation), a proportion similar to the one
reported previously [13]. MICs of imipenem show that 91%
(61/67) of the Mabs complex strains display moderate
susceptibility and 9% (6/67) were resistant to the drug.
MIC50 and MIC90 were consistent with those reported
recently [14]. Eighty-six per cent (58/67) of the isolates were
susceptible to cefoxitin with a MIC90 value of 32 mg/L, slightly
lower than the one reported earlier [14]. Regarding tigecy-
cline, 61% (41/67) of all strains show MIC ≤ 4 mg/L, slightly
lower than that reported previously [13]. Among all seven
drugs, MIC50 and MIC90 values were found to be the lowest
with clofazimine (2 and 4 mg/L, respectively).
Given the multiple and long antibiotic exposures experi-
enced by CF patients, one may speculate that strains from CF
patients exhibit higher antimicrobial resistance than those
from non-CF patients, resulting in more resistant strains. Table
S1 presents the drug susceptibility patterns of Mabs complex
strains with (n = 35) and without underlying CF (n = 27). Only
small variations were observed between the two groups with,
at most, a two-fold difference in the MIC90 values, consistent
with another study [13].
Clofazimine is currently registered for use in leprosy
treatment and also to treat multidrug-resistant tuberculosis
[15]. Two studies emphasized the synergistic activity of
clofazimine when given with amikacin against Mabs [16,17].
Moreover, tigecycline given for more than 1 month as part of
a multidrug regimen resulted in improvement in more than
60% of patients with Mabs and M. chelonae infections [18]. We
thus explored the effect of clofazimine/tigecycline treatment
against Mabs using the checkerboard microdilution technique
in CAMHB. Susceptibility to clofazimine was determined at 4,
2, 1, 0.5, 0.25, 0.125, 0.0625 and 0.031 mg/L, keeping
tigecycline constant at 4 mg/L. Susceptibility to tigecycline
TABLE 1. MICs (mg/L) of a panel of seven drugs in Cation-Adjusted Mueller-Hinton broth for 67 clinical isolates belonging to the
M. abscessus complex
Drug Clinical isolates (number of strains)
Number of strains with indicated MIC
MIC50 MIC90 Resistance (%)2 4 8 16 32 64
Amikacin All (67) 21 11 12 12 8 3 8 32 4
M. abscessus (42) 12 9 5 8 6 2 4 32 5
M. bolletii (4) 2 1 1 4 16 0
M. massiliense (21) 7 2 6 3 2 1 8 32 5
Smooth (50) 20 7 8 8 4 3 4 32 6
Rough (17) 1 4 4 4 4 8 32 0
Linezolid All (67) 30 14 14 4 5 4 16 7
M. abscessus (42) 19 7 10 2 4 4 16 10
M. bolletii (4) 3 1 2 8 0
M. massiliense (21) 9 7 3 1 1 4 8 5
Smooth (50) 27 6 11 3 3 2 16 6
Rough (17) 3 8 3 1 2 4 32 12
Clarithromycina All (67) 32 13 8 6 7 1 2 16 12
M. abscessus (42) 17 8 7 5 5 4 16 17
M. bolletii (4) 4 2 2 0
M. massiliense (21) 11 5 1 1 2 1 2 32 5
Smooth (50) 30 7 6 3 4 2 32 12
Rough (17) 2 6 2 3 3 1 8 32 12
Imipenem All (67) 7 44 10 6 8 16 9
M. abscessus (42) 5 25 6 6 8 32 14
M. bolletii (4) 1 3 8 8 0
M. massiliense (21) 1 16 4 8 8 0
Smooth (50) 5 35 8 2 8 8 4
Rough (17) 2 9 2 4 8 32 24
Cefoxitin All (67) 16 12 17 13 7 2 8 32 3
M. abscessus (42) 8 7 11 10 5 1 8 32 2
M. bolletii (4) 3 1 2 2 0
M. massiliense (21) 5 5 5 3 2 1 4 32 5
Smooth (50) 15 7 13 9 4 2 8 32 4
Rough (17) 1 5 4 4 3 8 32 0
Clofazimine All (67) 53 8 6 2 4
M. abscessus (42) 34 4 4 2 4
M. bolletii (4) 3 1 2 4
M. massiliense (21) 16 3 2 2 4
Smooth (50) 38 7 5 2 4
Rough (17) 15 1 1 2 4
Tigecycline All (67) 20 21 18 8 4 8
M. abscessus (42) 10 15 13 4 4 8
M. bolletii (4) 2 1 1 2 8
M. massiliense (21) 8 5 5 3 4 16
Smooth (50) 17 15 12 6 4 8
Rough (17) 3 6 6 2 4 8
aData for clarithromycin are presented after 4 days only of incubation. Bold types indicate resistant categories (except to clofazimine and tigecycline) of interpretive criteria for
each antimicrobial agent, according to the 2011 CLSI breakpoints. MIC50 and MIC90 are expressed as mean values of triplicates.
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was assessed at 16, 8, 4, 2, 1, 0.5, 0.25 and 0.0625 mg/L with
clofazimine at 1 mg/L. The effect was evaluated by calculating
the fractional inhibitory concentration (FIC), defined as the
sum of the MIC of each drug when used in combination
divided by the MIC of the drug when used alone. Table 2
shows the MIC of clofazimine and tigecylcine, alone or in
combination, against 19 clinical isolates. Synergism was found
in 42% of the strains (8/19), and ten strains exhibited
indifference, albeit the MIC for tigecycline was reduced when
administered with clofazimine compared with that for
tigecycline alone. One M. massiliense strain showed an antag-
onistic effect.
Activity of amikacin is considerably improved when com-
bined with clofazimine [16,17]. Previous studies suggested that
tigecycline does not have a good synergistic effect against RGM
when combined with amikacin but displays high synergy with
clarithromycin [19]. We report here the first combined
activities of clofazimine and tigecycline with clear synergy in
42% of the strains tested. Although additional studies are
required on a higher number of isolates, our data suggest that
both drugs can be combined and used as an alternative or
sequential medication for the treatment of drug-resistant
strains or in difficult situations. However, synergy should be
tested, rather than assumed, prior to treatment and care
regarding the side-effects might also be taken into consider-
ation. Efficient clofazimine analogues are also available, thus
offering more alternatives in the long term. The clofazimine/
tigecycline combination should next be assessed in animal
models. In this context, we recently developed the zebrafish
embryo infection model for in vivo drug assessment against
Mabs [20].
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